Target intelligence / Profile preview

Follistatin (FST) (FST)

Target
FST
Molecular classification
TGF-beta superfamily antagonist, Activin-binding protein, Other
01

Overview

Follistatin is a secreted glycoprotein that serves as a potent endogenous antagonist of several members of the transforming growth factor-beta (TGF-beta) superfamily, most notably activin A and myostatin (GDF-8) (UniProt P19883). By binding these ligands with nearly irreversible affinity, follistatin prevents them from engaging their cognate receptors, thereby modulating diverse physiological processes including muscle growth, inflammation, and reproductive hormone secretion. In skeletal muscle, follistatin promotes hypertrophy and increases strength by neutralizing myostatin, a key negative regulator of muscle mass. This mechanism has made it a primary target for therapeutic intervention in muscle-wasting diseases such as Duchenne and Becker muscular dystrophies, as well as inclusion body myositis (NCT02726217). Beyond muscle, follistatin is involved in liver regeneration, wound healing, and the regulation of the pituitary-gonadal axis. Clinical development focuses on gene therapy delivery systems and modified protein constructs to enhance muscle mass and function while managing potential systemic effects on other TGF-beta-regulated pathways.

Other names
Activin-binding proteinFSFST315FST288FST344
02

Mechanism of action

Follistatin acts as a high-affinity binding protein that sequesters ligands of the TGF-beta superfamily, including Activin A, Myostatin (GDF-8), and GDF-11 (UniProt P19883). By masking the receptor-binding sites of these ligands, it prevents them from activating the Activin receptor type IIA and IIB (ActRIIA/B) complex, thereby inhibiting the SMAD2/3 signaling pathway that typically restricts muscle growth and promotes fibrosis.

03

Biological functions

Signal transductionCell proliferationMuscle growth regulationFSH secretion inhibitionOther
04

Disease associations

CancerInflammationMuscular dystrophySarcopeniaOther
05

Safety considerations

Suppression of follicle-stimulating hormone (FSH) levelsPotential impact on reproductive functionRisk of promoting tumor progression in certain cancersOff-target effects on bone metabolism
06

Interacting drugs

rAAV1-FS344

1 more in the full profile.

07

Biomarkers

Serum Follistatin levelsActivin A levelsMyostatin levelsLean body massCreatine kinase levels

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Follistatin (FST) (FST).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Follistatin (FST) (FST).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call